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Abstract
MHC-encoded HLA-DMA and -DMB molecules are atypical MHC chains that play an essential role In
antigen presentation by MHC class II molecules. They resemble both MHC class I and II molecules
but are not expressed at the cell surface. From the study of MHC class II regulatory mutants, it was
found recently that two novel transactivators, CIITA and RFX5, are essential for the control of MHC
class II gene expression. We report here that CIITA and RFX5, although operating at different levels
of transcrlptlonal control, are also both essential regulators of HLA-DMA and -DMB genes. This Is
true for both the constitutive and the induclble mode of DM gene expression. Indeed, both CIITA
and RFX5 cDNA can correct the HLA-DMA and -DMB gene expression defect In the respective
regulatory mutants. The Involvement of these two transcription factors accounts for the coordinate
expression of MHC class II and HLA-DM, two sets of molecules that perform quite different
functions in the overall process of antigen presentation.
Introduction
The DMA and DMB genes were first identified as non-classical
MHC genes, mapping to the MHC class II region. From their
predicted amino acid sequence, HLA-DM molecules are
neither typical MHC class I nor class II molecules, although
they show sequence homology to both (1). Their promoters
resemble MHC class II promoters (1). The observation that
DMA and DMB genes are able to correct certain defects in
somatic cell mutants of antigen presentation revealed an
interesting role for HLA-DM in the process of assembly of
MHC class ll-peptide complexes (2,3) and therefore in antigen
presentation to CD4 T lymphocytes. DMA and DMB molecules
form a stable dimer, which, unlike MHC class II molecules, is
not expressed at the cell surface (4). Since MHC class II
mediated antigen presentation to CD4 T cells depends on
tight control of MHC class II gene expression, the functional
role of HLA-DM molecules in antigen presentation obviously
raises the issue of the regulation of DM genes, in correlation
with that of MHC class II genes.
Our understanding of the mechanisms of MHC class II
gene regulation, both constitutive and inducible, and of
some of the regulatory factors involved, has benefited from
a systematic study of a rare disease, MHC class II deficiency
or bare lymphocyte syndrome (BLS) (5-8). In this disease, a
total absence of MHC class II expression leads to severe
primary immunodeficiency. We have shown that MHC class
II deficiency results from distinct regulatory defects, affecting
frans-acting regulatory factors (7). Recently two such factors,
defective in two distinct forms of BLS (complementation
groups A and C), have been identified by complementation
cloning and characterized structurally and functionally (9,10).
The MHC class II transactivator CIITA is mutated in patients
from group A and transfection of its cDNA into patient cell
lines restores normal expression of all class II genes (9).
Similarly, RFX5, a DNA binding protein of the RFX family, is
mutated in patients from group C; transfection of its cDNA
restores MHC class II expression in patient cells (10). More-
over, it has been shown that CIITA is the mediator of inducible
expression of MHC class II genes, as in the induction of MHC
class II genes by IFN-y(H).
Because of the role of HLA-DM genes in antigen presenta-
tion, and despite the fact that HLA-DM molecules are structur-
ally very different from MHC class II molecules, it is of interest
to explore whether the expression of HLA-DM genes is also
controlled by these two novel MHC class II transactivators.
Here we show that CIITA and RFX5 control both constitutive
expression of HLA-DM genes in B lymphocytes and their
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expression in cells where MHC class II genes are inducible.
Thus the same two regulatory factors, although acting at
different levels of transcriptional activation (8), control the
expression of both MHC class II and HLA-DMA and -DMB
genes.
Methods
Plasmids construction
The plasmids used for transfection were EBO-Sfi/CIITA (9),
EBO-Sfi (9), EBO-Sfi/RFX5 (10) and SRaNEO/CIITA (V. Steimle
and B. Mach, unpublished results). The riboprobes used to
detect DM mRNA were generated by inserting respectively a
Bs/XI fragment from DMA (positions 98-477) and a Sma-
HaeH fragment from DMB (positions 233-634) into the EcoRV
site of the Bluescript KS vector. The riboprobes for detection
of HLA-DRA, CIITA and TATA-binding protein (TBP) mRNA
have been previously described (9,12,13).
Cell cultures and transfections
HeLa cells were grown in Dulbecco's minimum essential
medium supplemented with 10% FCS 10 U/ml penicillin,
10 ng/ml streptomycin and 2 mM L-glutamine. IFN-y(500 U/
ml) was added for the time course experiment. The B
lymphoma cell line RAJI and the EBV-transformed B cell lines
Mann, BLS-2, SJO, Ro and BLS-1 were grown in RPMI-
1640 medium also supplemented with 10% FCS, penicillin,
streptomycin and glutamine. Cells were incubated at 37°C in
5% CO2.
BLS-2 transfectant EBO-Sfi/CIITA (9) and SJO trans-
fectants (EBO-Sfi/RFX5 and EBO/Sfi) (10) were generated
as described (9). Briefly, cells were transfected by electro-
poration and hygromycin resistant cells were analyzed by
FACS. Stable integrative transfectants were generated with
the expression vector SRaNEO/CIITA, with the following modi-
fications to the procedure: HeLa cells were transfected by
the CaPO4 method, selected with G418 and HLA-DR positive
cells enriched by sorting with Dynabeads and subsequently
cloned by limiting dilution.
RNase protection assays
Total RNA was extracted from frozen cell pellets by guanidium
isothiocyanate lysis and CsCI step gradient centrifugation
(14). To generate riboprobes, the cDNA-containing plasmids
were linearized and transcribed with T3 (DMB), T7 (DMA,
CIITA) or SP6 RNA polymerase (DRA, TBP) in the presence
of [32P]UTP. The specific activity of the DRA and the DM
probes was reduced compared with TBP as specified in the
figure legends. Hybridization of 5 ng of total RNA completed
to 50 ng with yeast RNA with 100,000-400,000 c.p.m. of each
probe was performed in 80% formamide, 40 mM PIPES
pH 6.4, 0.4 M NaCI and 1 mM EDTA, at 50°C overnight. The
samples were then digested with 23 |ig RNase A and 3.7 U
RNase T1 for 30 min at 30°C. After subsequent treat-
ment with 50 jig proteinase K in the presence of 1 % SDS for
15 min at 37°C, the protected RNA fragments were extracted
twice with phenol-chloroform, ethanol precipitated and
resolved on denaturing 6% polyacrylamide-8 M urea gels (15).
Results
Time course of IFN-y induced expression of the DMA and
DMB genes parallels that of the DRA gene
The features of MHC class II gene induction by IFN-Y n a v e
been thoroughly studied and are characterized by both a
prolonged lag period and dependence on de novo protein
synthesis (12,16,17). Although the structure and function of
the DMA and DMB genes are quite distinct from those of
MHC class II genes, their promoters are similar in contain-
ing the typical class II promoter elements X and Y and it has
been shown that HLA-DM expression can be induced by
IFN-y (1). It was therefore of interest to further clarify the
mechanism of DMA and DMB induction by IFN-y, first by a
comparison of the time course of their expression in IFN-Y
treated cells to that of MHC class II genes. RNase protection
analysis of the mRNA extracted from HeLa cells incubated
between 2 and 72 h with IFN-y reveals the appearance of
DMA and DMB expression after 12 h. The level of expression
increases up to 48 h and remains stable after 72 h (Fig. 1).
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Fig. 1. Time course of HLA-DMA and -DMB mRNA induction in HeLa
cells treated with IFN-y. The induction of DMA and DMB was compared
with that of the IFN-y inducible genes DRA and CIITA. The quantity
and quality of the RNA were controlled by hybridization to a TBP
specific probe. Specific activity of the DRA probe was reduced four-
fold, relative to the other probes.
Both RFX5 and CIITA regulate HLA-DM genes 1297
The kinetics of DMA and DMB gene induction therefore strictly
parallel that of the DRA gene (Fig. 1), with a lag period of 12
h before first detection of mRNA expression. This contrasts
with the time course of IFN-y induced expression of the MHC
class II transactivator gene CIITA, which is already detectable
2 h after addition of IFN-y to the cell culture (Fig. 1).
Constitutive DMA and DMB gene expression is defective in
cell lines from patients with BLS
HLA-DMA and -DMB genes have been shown to be constitu-
tively expressed in a B lymphoma cell line by Northern blot
analysis (1). MHC class II deficiency (BLS) is a genetically
heterogeneous disease which can be subdivided into at least
three complementation groups, as established by cell fusion
experiments (18,19) and by complementation with two of the
regulatory genes involved (9,10). It was therefore of interest
to analyze the status of HLA-DM gene expression in each of
these three complementation groups.
RNase protection analysis of DMA and DMB expression in
B cell lines derived from patients with BLS revealed a complete
lack of expression in patient BLS-2, representative of comple-
mentation group A (Fig. 2, lane 5), Ro and SJO (group C)
(Fig. 2, lanes 3 and 4) and BLS-1 (group B) (Fig. 2, lane 2).
Lack of expression of DM mRNA in patient SJO had been
reported earlier (20). This contrasts with the constitutive
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expression of the DM genes in the B lymphoma cell line RAJI
(Fig. 2, lane 1) and the EBV transformed B cell line Mann
(Fig. 2, lane 6). We also confirm the lack of expression of
the HLA-DRA gene in all three complementation groups
described. We conclude therefore that the transacting defects
responsible for each of the three BLS complementation groups
also result in the lack of HLA-DM gene expression.
Constitutive DMA and DMB expression can be restored in
BLS cell lines by cDNA encoding the regulatory factors CIITA
orRFX5
Two molecular and genetic defects responsible for BLS
have been recently characterized (9,10). The MHC class II
transactivator CIITA is mutated in several cell lines from BLS
complementation group A (9; S. Bontron, V. Steimle, C. Ucla
and B. Mach, unpublished results). Transfection of these cell
lines with CIITA cDNA allowed restoration of MHC class II
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Fig. 2. HLA-DMA and DMB genes are not expressed in cell lines
from patients with the BLS. Lane 1: RAJI; lane 2: BLS-1; lane 3: Ro;
lane 4: SJO; lane 5: BLS-2; lane 6: Mann. Specific activities of the
DM and DRA probes were reduced eight- and 25-fold respectively.
Fig. 3. Restoration of DMA and DMB expression in cell lines from
patients with BLS by the relevant regulatory genes. The cell line
from patient BLS-2 is corrected by transfection of CIITA cDNA,
whereas the cell line from patient SJO is corrected by transfection of
RFX5 cDNA. Lane 1: BLS-2; lane 2: BLS-2 transfected with CIITA;
lane 3: SJO transfected with control plasmid; lane 4: SJO transfected
with RFX5. Specific activity of the DRA probe was reduced 25-fold.
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gene expression. Similarly, the transcription factor RFX5 is
mutated in three patient cell lines from BLS complementation
group C (10; W. Reith, J. Vlllard and B. Mach, unpublished
results) and transfection of these cell lines with RFX5 cDNA
also restores MHC class II gene expression. By RNase
protection analysis, it was possible to document correction
of both DMA and DMB constitutive gene expression in cell
lines derived from BLS patients transfected with the relevant
regulatory gene (Fig. 3). In the cell line BLS-2, HLA-DM
expression is restored through transfection of CIITA cDNA
(Fig. 3, lanes 1 and 2). In the cell line SJO, transfection of
RFX5 cDNA restores the expression of DMA and DMB (Fig.
3, lane 4), while transfection of a control plasmid does not
(Fig. 3, lane 3). Correction for the expression of the DRA gene
is shown as a control.
DMA and DMB gene expression can be induced in HeLa
cells by transfection of the MHC class II transactivator CIITA
The MHC class II transactivator CIITA has been shown to be
an essential mediator not only of constitutive but also of
inducible MHC class II gene expression (11). Transfection of
CIITA cDNA in a variety of MHC class II negative, IFN-y
inducible cell lines is sufficient, in the absence of IFN-y, to
induce expression of MHC class II genes in fibroblastic,
monocytic and melanoma cell lines (11).
The effect of CIITA transfection on DMA and DMB gene
expression was therefore studied in an IFN-y inducible cell
line by quantitative mRNA assays. RNase protection analysis
on mRNA from HeLa cells shows the expression of the DMA
(Fig. 4, lane 6) and DMB (Fig. 4, lane 4) gene products in
stable CIITA transfectants. No DM gene expression can be
detected in untransfected cells (Fig. 4, lane 3 and 5). The
expression of DRA (Fig. 4, lane 1 and 2) and CIITA mRNA
(Fig. 4, lanes 7 and 8) is shown as a control of transfection
efficiency. Following completion of this study, it was reported
elsewhere that CIITA can indeed induce expression of HLA-
DM in HeLa cells (21). We conclude that both HLA-DMA and
DMB genes can be induced by CIITA in these MHC class II
negative cells.
Discussion
The MHC class II locus on the short arm of chromosome 6
contains a cluster of genes encoding structural MHC class II
molecules as well as proteins involved in exogenous and
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Fig. 4. Transfection of HeLa cells with CIITA cDNA induces DMA and
DMB expression. Lanes 1,3,5 and 7: untransfected cells. Lanes 2,
4, 6 and 8: CIITA transfected HeLa cells. The specific activities of
the DM, DRA and CIITA probes were reduced eight- 40- and two-
fold respectively, compared with the TBP probe.
endogenous antigen processing pathways [reviewed in (22)].
One of the hypotheses put forward to explain the maintenance
of this spatial organization is the need for coordinate expres-
sion of multiple MHC genes operating at different levels of
the complex antigen presentation pathway where all are
required to mount an efficient immune response (23).
Our results reveal a coordinate expression of the DMA and
DMB genes with the structural MHC class II genes in both
constitutive and inducible modes of expression. More
importantly, we demonstrate that two essential regulatory
factors, recently shown to control MHC class II gene expres-
sion, CIITA and RFX5, are both essential for HLA-DM gene
expression. First, mutations in either one of these two regu-
latory genes abolish DM gene expression. More directly,
transfection with either CIITA or RFX5 cDNA can restore DM
gene expression in regulatory mutants and, in the case of
CIITA, induce DM expression in MHC class II negative cells.
RFX5 is a transcription factor whose binding to the X box of
MHC class II promoters is essential for activity (10), while
CIITA does not bind to class II promoters but is required for
their transcriptional activity. At these two different levels of
transcriptional control, regulation of both MHC class II and
HLA-DM genes involve, therefore, the same mechanisms.
These mechanisms and transcription factors are very differ-
ent from those involved in the control of MHC class I gene
expression. As expected, MHC class I genes and the MHC
encoded proteasome genes, are expressed normally in BLS
cells and are thus not controlled by the same transcription
factors (6,20).
The role of HLA-DM molecules in antigen presentation and
the coordinate regulation of DM genes with MHC class 11 genes
can explain the antigen presentation defective phenotype
observed with BLS cells transfected only with HLA-DR cDNAs
(24). In addition to what is observed in B lymphocytes, and
in agreement with the results of Chang and Flavell (21), the
data show that expression of CIITA in HeLa cells, without IFN-
y stimulation, can induce not only MHC class II genes but
also HLA-DMA and -DMB expression. Expression of CIITA,
and thus of the different genes controlled by CIITA, in non-
professional APC can therefore provide these cells with the
set of molecules known to be required for an operational
MHC class II peptide loading compartment (25).
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